JPWO2019178006A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178006A5 JPWO2019178006A5 JP2020548778A JP2020548778A JPWO2019178006A5 JP WO2019178006 A5 JPWO2019178006 A5 JP WO2019178006A5 JP 2020548778 A JP2020548778 A JP 2020548778A JP 2020548778 A JP2020548778 A JP 2020548778A JP WO2019178006 A5 JPWO2019178006 A5 JP WO2019178006A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- antigen
- cell
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188260A JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641987P | 2018-03-12 | 2018-03-12 | |
| US62/641,987 | 2018-03-12 | ||
| US201862738941P | 2018-09-28 | 2018-09-28 | |
| US62/738,941 | 2018-09-28 | ||
| US201962794516P | 2019-01-18 | 2019-01-18 | |
| US62/794,516 | 2019-01-18 | ||
| PCT/US2019/021705 WO2019178006A2 (en) | 2018-03-12 | 2019-03-11 | Intracellular delivery of biomolecules to modify immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Division JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517813A JP2021517813A (ja) | 2021-07-29 |
| JPWO2019178006A5 true JPWO2019178006A5 (https=) | 2022-03-18 |
| JP2021517813A5 JP2021517813A5 (https=) | 2022-03-18 |
| JP7595827B2 JP7595827B2 (ja) | 2024-12-09 |
Family
ID=66102189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548778A Active JP7595827B2 (ja) | 2018-03-12 | 2019-03-11 | 免疫応答を改変するための生体分子の細胞内送達 |
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240374654A2 (https=) |
| EP (1) | EP3765068A2 (https=) |
| JP (2) | JP7595827B2 (https=) |
| KR (1) | KR20200130835A (https=) |
| CN (1) | CN112135627A (https=) |
| AU (2) | AU2019234550B2 (https=) |
| BR (1) | BR112020018612A2 (https=) |
| CA (1) | CA3093828A1 (https=) |
| CO (1) | CO2020012584A2 (https=) |
| CR (1) | CR20200460A (https=) |
| IL (1) | IL277188B2 (https=) |
| MA (1) | MA52010A (https=) |
| MX (1) | MX2020009439A (https=) |
| PH (1) | PH12020551436A1 (https=) |
| SG (1) | SG11202008864VA (https=) |
| TW (1) | TW202003019A (https=) |
| WO (1) | WO2019178006A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| JP7602702B2 (ja) | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
| US12599656B2 (en) | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP6884450B2 (ja) * | 2019-02-14 | 2021-06-09 | 学校法人獨協学園獨協医科大学 | Ｔ細胞ワクチン |
| CA3131701A1 (en) | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| US11679388B2 (en) | 2019-04-08 | 2023-06-20 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
| AU2021272340A1 (en) | 2020-05-11 | 2022-12-08 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
| EP4188425B1 (en) | 2020-07-29 | 2025-05-14 | Stemcell Technologies Canada Inc. | Methods to stimulate immune responses to mutant ras using anucleate cells |
| WO2022026620A1 (en) | 2020-07-29 | 2022-02-03 | Sqz Biotechnologies Company | Methods to stimulate immune responses to mutant ras using nucleated cells |
| TW202241466A (zh) | 2020-12-29 | 2022-11-01 | 美商Ｓｑｚ生物科技公司 | 以經修飾ｐｂｍｃ治療癌症之方法 |
| JP2024503279A (ja) | 2020-12-29 | 2024-01-25 | スクイーズ バイオテクノロジーズ カンパニー | Ｐｂｍｃの凍結保存のための製剤 |
| US20220233676A1 (en) * | 2020-12-29 | 2022-07-28 | Sqz Biotechnologies Company | Formulations of activating antigen carriers |
| US20220296691A1 (en) | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
| CN115252772A (zh) * | 2021-04-30 | 2022-11-01 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
| WO2023010090A1 (en) | 2021-07-29 | 2023-02-02 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| WO2023087009A1 (en) | 2021-11-11 | 2023-05-19 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| CA3262748A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | IMPROVED ANTIGEN-PRESENTING CELL FORMULATIONS |
| CA3262756A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | CANCER TREATMENT METHODS WITH ENHANCED ANTIGEN-PRESENTING CELLS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528838A (ja) * | 2003-12-24 | 2007-10-18 | ライデン ユニバーシティ メディカル センター | 腫瘍特異的ワクチンとしての合成タンパク質 |
| ES2482192T3 (es) * | 2007-05-31 | 2014-08-01 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacunación intradérmica del péptido de HPV |
| WO2009039125A1 (en) * | 2007-09-17 | 2009-03-26 | The Schepens Eye Research Institute, Inc. | Use of ocular neuropeptides as immune adjuvants |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| CN107058101B (zh) * | 2011-10-17 | 2021-06-01 | 麻省理工学院 | 细胞内传递 |
| US20170212116A1 (en) * | 2014-01-31 | 2017-07-27 | Ulisse Biomed Srl | Biosensors for the detection of infection and associated maladies |
| JP7523203B2 (ja) * | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| ES2930017T3 (es) | 2015-09-04 | 2022-12-05 | Sqz Biotechnologies Co | Suministro intracelular de biomoléculas mediado por una superficie con poros |
| CN108779475A (zh) * | 2016-01-12 | 2018-11-09 | Sqz生物技术公司 | 复合物的细胞内递送 |
| US12599656B2 (en) * | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
-
2019
- 2019-03-11 EP EP19716612.7A patent/EP3765068A2/en active Pending
- 2019-03-11 CR CR20200460A patent/CR20200460A/es unknown
- 2019-03-11 WO PCT/US2019/021705 patent/WO2019178006A2/en not_active Ceased
- 2019-03-11 CN CN201980030600.3A patent/CN112135627A/zh active Pending
- 2019-03-11 AU AU2019234550A patent/AU2019234550B2/en active Active
- 2019-03-11 CA CA3093828A patent/CA3093828A1/en active Pending
- 2019-03-11 BR BR112020018612-0A patent/BR112020018612A2/pt unknown
- 2019-03-11 US US16/980,339 patent/US20240374654A2/en active Pending
- 2019-03-11 MA MA052010A patent/MA52010A/fr unknown
- 2019-03-11 SG SG11202008864VA patent/SG11202008864VA/en unknown
- 2019-03-11 JP JP2020548778A patent/JP7595827B2/ja active Active
- 2019-03-11 MX MX2020009439A patent/MX2020009439A/es unknown
- 2019-03-11 TW TW108108098A patent/TW202003019A/zh unknown
- 2019-03-11 IL IL277188A patent/IL277188B2/en unknown
- 2019-03-11 KR KR1020207028580A patent/KR20200130835A/ko not_active Ceased
-
2020
- 2020-09-11 PH PH12020551436A patent/PH12020551436A1/en unknown
- 2020-11-03 CO CONC2020/0012584A patent/CO2020012584A2/es unknown
-
2024
- 2024-10-25 JP JP2024188260A patent/JP2025020210A/ja active Pending
-
2026
- 2026-03-03 AU AU2026201618A patent/AU2026201618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517813A5 (https=) | ||
| IL277188B2 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| JPWO2019178006A5 (https=) | ||
| JP2021517895A5 (https=) | ||
| JP7497054B2 (ja) | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 | |
| JPWO2019178005A5 (https=) | ||
| CA2730742C (en) | Hiv vaccine based on targeting maximized gag and nef to dendritic cells | |
| Batista-Duharte et al. | Immune checkpoint inhibitors for vaccine improvements: current status and new approaches | |
| US8323655B2 (en) | Identification of antigenic peptides from multiple myeloma cells | |
| TW202146440A (zh) | 經工程化以過度表現細胞訊號傳遞路徑調節物之免疫細胞及其用途 | |
| US20230190812A1 (en) | Engineered t cell receptors and methods of use | |
| EP4570256A2 (en) | Engineered t cell receptors targeting egfr antigens and methods of use | |
| JP2022514116A (ja) | 新規な癌抗原及び方法 | |
| Gagliardi et al. | Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro | |
| CN116368222A (zh) | 破坏cd28-唾液酸糖苷配体复合物以增强t细胞活化 | |
| Schütz et al. | MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth | |
| IL324813A (en) | T-cell receptors that bind to peptides displaying HPV16-, MART1-, CMV-, EBV-, or influenza | |
| CA3172895A1 (en) | Engineered t cell receptors and methods of use | |
| US20260007698A1 (en) | Peptides and engineered t cell receptors targeting vcy antigen and methods of use | |
| Lycke et al. | ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 development and protection against influenza virus infection | |
| KR20240046834A (ko) | Fanci, rad51, 및 pbk 항원을 표적화하는 펩타이드 및 가공된 t 세포 수용체 및 이의 사용 방법 | |
| CA3236237A1 (en) | Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use | |
| RU2020132524A (ru) | Способы лечения заболеваний, ассоциированных с впч | |
| WO2025101705A1 (en) | Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use | |
| Popple | The tumour microenvironment influences antigen specific T cell transmigration |